Specialty pharmaceuticals have become increasingly important in the global pharmaceutical landscape. Numerous large pharmaceutical companies are moving towards developing therapies for specialty markets, which are attractive owing to factors including the established commercial track record and lower commercial infrastructure costs. In this article, we analyse the key drivers of commercial success and failure for specialty pharmaceuticals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nrd2594 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab (Ophthalmol Retina. 2024;8:733-743).
Ophthalmol Retina
January 2025
Department of Ophthalmology, Chi Mei Medical Center, Tainan, Taiwan; School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Population Health Data Center, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Off TARGET Effects in Stent Comparison Trials: Looking Beyond the Primary Endpoint Analysis.
J Am Coll Cardiol
December 2024
Department of Cardiology and Cardiovascular Research Institute, Mater Private Network, Dublin, Ireland; School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland. Electronic address:
Human Brucellosis among the farmworkers in Cilawu and Boyolali, Indonesia.
Vet Ital
September 2024
Professor Nidom Foundation, Surabaya, Indonesia.
Brucellosis is a neglected infectious disease caused by animals and is becoming a public health problem in developing countries. There are limited case reports of human brucellosis in Indonesia because the symptoms are not specific. This study investigated the association between serological tests for brucellosis among workers and their knowledge, attitude, and behavior.
View Article and Find Full Text PDFCorrection: Köksal et al. Interplay Between HIV and Human Pegivirus (HPgV) Load in Co-Infected Patients: Insights from Prevalence and Genotype Analysis. 2024, , 5.
Viruses
December 2024
Department of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34093, Türkiye.
In the original publication [...
View Article and Find Full Text PDFCharacterization of Hepatitis B Virus Transcripts in Chronically HBV-Infected Chimpanzees and Patients Treated with ARC-520 siRNA Demonstrates Transcriptional Silencing of cccDNA.
Viruses
December 2024
Department of Medicine & State Key Laboratory of Liver Research, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.
Full-length hepatitis B virus (HBV) transcripts of chimpanzees and patients treated with multidose (MD) HBV siRNA ARC-520 and entecavir (ETV) were characterized by single-molecule real-time (SMRT) sequencing, identifying multiple types of transcripts with the potential to encode HBx, HBsAg, HBeAg, core, and polymerase, as well as transcripts likely to be derived from dimers of dslDNA, and these differed between HBeAg-positive (HBeAg+) and HBeAg-negative (HBeAg-) individuals. HBV transcripts from the last follow-up ~30 months post-ARC-520 treatment were categorized from one HBeAg+ (one of two previously highly viremic patients that became HBeAg- upon treatment and had greatly reduced cccDNA products) and four HBeAg- patients. The previously HBeAg+ patient received a biopsy that revealed that he had 3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!